Business Spend Management Improves Visibility and Control Over Spend for Financial Leaders
Closing the books can be a tedious, manual process when accrual balances don’t match AP balances and a backlog of invoices cause an increase in resource hours.
Get insight on how Salesforce and Ionis Pharmaceuticals leverage business spend management to streamline the financial close.
Read this eBook to learn how to:
• Automate spend processes to cut heavy manual workloads
• Gain full visibility and control over spend
• Move from transactional “spreadsheet jockey” to strategic management
• Minimize risk associated with missed accruals
Healthcare and Life Sciences organizations are using data to generate knowledge that helps them provide better patient care, enhances biopharma research and development, and streamlines operations across the product innovation and care delivery continuum. Next-Gen business intelligence (BI) solutions can help organizations reduce time-to-insight by aggregating and analyzing structured and unstructured data sets in real or near-real time.
AWS and AWS Partner Network (APN) Partners offer technology solutions to help you gain data-driven insights to improve care, fuel innovation, and enhance business performance.
In this webinar, you’ll hear from APN Partners Deloitte and hc1.com about their solutions, built on AWS, that enable Next-Gen BI in Healthcare and Life Sciences.
Join this webinar to learn:
How Healthcare and Life Sciences organizations are using cloud-based analytics to fuel innovation in patient care and biopharmaceutical product development.
How AWS supports BI solutions f
When a pharmaceutical company discovered its risks under the new Patient Protection and Affordable Care Act, it turned to Collaborative to comb and consolidate its data. The result: compliance and insight into new business opportunities, too, through a company-wide business data warehouse and enhanced business intelligence.
In a panel discussion at the 12th annual SAS Health Analytics
Executive Forum in May 2015, leaders from Dignity Health,
Horizon Blue Cross Blue Shield of New Jersey, Janssen
Pharmaceuticals and SAS shared what they have done to prove
the value of analytics to their business leaders – and what has
worked for them as they developed an analytic culture in their
organizations and put analytic insights to work.
To the casual observer, aircraft manufacturer Airbus UK and pharmaceutical giant GlaxoSmithKline (GSK) wouldn't appear to share a lot of common ground. Some would say that the worlds of building airplanes and producing the next blockbuster wonder-drug are light years apart. A closer look shows that these two organizations are more similar than one might initially think.
Cost reduction is a key criteria that executives often use when choosing initiatives to focus on. They are the ones that have the greatest potential to impact an organization's bottom line. Across life science organizations, a critical area for cost containment is training management.
This paper summarizes the results of a quantitative benchmarking survey to over 200 Life Science organizations. The study identifies the key compliance and performance improvement training topics they had addressed in 2011 along with key issues for 2012.
SOPs are critical to efficient manufacturing operations, quality control, and regulatory compliance. This paper reviews best practices for the Life Science industry for training on SOPs, and how learning management technology has the potential to improve learner retention through automated assessments.
Third party intermediaries have played starring roles in some of the most highly publicized global corruption trials. By any measure, third party intermediaries routinely rank high on the list of compliance worries for brand companies.
Good Manufacturing Practices (GMP) violations have become the new healthcare fraud as the Department of Justice (DOJ) tests out new legal theories under the False Claims Act (FCA). The Food and Drug Administration (FDA) has dusted off its regulatory authority to prosecute GMP violations.
Published By: Intermec
Published Date: Jun 20, 2013
This research, commissioned by Intermec and carried out by research company Vanson Bourne, surveyed 250 senior supply chain and distribution center managers at organizations with over 500 employees in the UK, France, Germany and North America. The interviews were conducted by telephone with respondents spanning industries including retail, manufacturing, distribution, transport, chemicals, logistics, pharmaceuticals, wholesale and FMCG. 50 interviews were conducted in each European country with 100 interviews taking place in North America during October 2012.
For life sciences businesses, the supply chain used to mean one thing: getting products from factory or warehouse to distributors or ultimate customers as quickly and economically as possible. Now, with today’s evolving regulatory environment, an increasingly globalized market, more complex health products, and an increased focus on the patient, pharmaceutical companies and medical device manufacturers are looking at their supply chain and logistics needs in a whole new way.
One-fourth of all healthcare products today are temperature-sensitive and that number is growing. For many pharmaceutical or biologic shipments, 2 degrees Celsius is all that separates medicine from becoming spoiled inventory and a costly write-off. Here are four risk mitigation strategies for temperature-sensitive shipments.
Top 5 Factors Every Bio-Tech and Pharmaceutical Company Must Keep in Mind.
Successfully launching a product in the U.S. requires a balance across commercial strategy, government programs, and contracting operations. While the market holds significant opportunity, there are also complexities that need to be considered prior to launch.
To prepare for the launch of your drug in the U.S. market, download a copy of Navigating the U.S. Government Market to help your organization remain compliant with government operational and pricing requirements.
Download this white paper for a deeper look into the growing question surrounding the pharmaceutical industry--If customer centricity is so widely accepted as a way to unlock significant financial gains, why are companies so slow to adopt it?
Research teams can spend nearly a decade looking for new biological targets. Then years more creating and testing new molecules that offer improved ways to fight the world’s viruses, bacteria and diseases. These processes are usually long and and require an immense amount of computing power. However, it doesn’t need to be this difficult. Download this case study to see how high performance cloud computing can accelerate pharmaceutical breakthroughs while still retaining a simplistic structure that is cost-effective to scale computer resources.
Most population health management strategies include initiatives to improve clinical outcomes and decrease the cost of care. Read this one-page interview with Dr. Tina Moen, Deputy Chief Health Officer at IBM Watson Health, as she shares the benefits and insights of collaborative medication management, including incorporating pharmacists in population health strategies.
Published By: Infoblox
Published Date: Jun 18, 2015
The whitepaper delivers a pragmatic analysis of cloud reality that explains:
-The factors that could make your cloud initiative fail
-The necessity of automating core network services
-The results a global pharmaceutical firm achieved
Download and learn how to reclaim the promised benefits of private and hybrid cloud.
But what seems like a spoon full of sugar is often a tough pill to swallow when you consider regulatory requirements from agencies like the FDA for use of these networks. Adopting new technologies that allow employees to share information and exchange ideas with each other and with your customers is often the best way to achieve better business results, but doing so can involve considerable risk. That’s because the content people create using these technologies is subject to the scrutiny of regulators, legislators, and litigators. On top of that, increasing litigation has made it a business requirement to consider solutions that help bring down skyrocketing legal costs. Pharmaceuticals companies must be knowledgeable of, and abide by, specific information retention regulations in every country where they do business, including those countries that prohibit data from leaving the countries’ borders. Not having technology in place to help manage these requirements and increasing risks, or
Social Media Risks and Benefits for the Pharmaceuticals Industry
Drug makers are just beginning to realize how social networks can improve business processes. Social media helps your organization share information and exchange ideas with your customers quickly, but doing so can involve considerable risk. That’s because social media is subject to the scrutiny of regulators, legislators, and litigators. So, what seems like a spoon full of sugar is often a tough pill to swallow when you consider regulatory requirements from agencies like the FDA. On top of that, increasing litigation has made it a business requirement to consider solutions that help bring down skyrocketing legal costs. Not having technology in place to help manage these requirements and increasing risks, or doing so without careful planning, can be a costly mistake.
Read this paper to gain an understanding of:
What the regulatory landscape of the pharmaceuticals industry looks like
What concerns you should be aware of f
St. Joseph’s Hospital Health Center has a total of 310 refrigerators throughout the organization. These items require strict temperature ranges for quality patient care and safety. Regulatory agencies perform audits requiring logs of temperature monitoring and corrective actions.
Read this case study to learn about how St. Joseph's deployed the wireless AeroScout Environmental Monitoring solution to leverage its wireless network by working with STANLEY Healthcare.
Published By: BlackLine
Published Date: Aug 06, 2018
The biotechnology and pharmaceutical industry is among the most heavily regulated industries in the world, challenged by evolving regulations, complex compliance requirements and close regulatory scrutiny. At the same time, companies must address the market pressures of globalization, the use of predictive data analytics and digital technologies, and the industry’s ongoing consolidation. In this challenging environment, confidence in internal controls is crucial.